GSK to file Jemperli for rectal cancer after phase 3 readout
GSK to file Jemperli for rectal cancer after phase 3 readout Phil.Taylor Mon, 13/07/2026 - 11:42
Read the full articleYou might also wanna read
GSK Achieves Promising Results in Rectal Cancer Trial with Jemperli
Related Stocks: GSK
GSK’s Jemperli meets main goal in mid-stage rectal cancer trial
July 13 (Reuters) - GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rat
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
Quicksilver II Pilot Study
Conditions : Stage II Rectal Cancer; Stage III Rectal Cancer Interventions : Procedure: Direct-to-surgery (i.e., no neoadjuvant chemotherapy
Evaluating the Optimal Timing of Trans-Anal Irrigation for Low Anterior Resection Syndrome Post-rectal Cancer Surgery
Conditions : Low Anterior Resection Syndrome (LARS) Interventions : Device: Water-based transanal irrigation system Sponsors : Simona Ascane
SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer
Conditions : Rectal Cancer; Rectal Adenocarcinoma; Rectal Cancer Patients; Rectal Cancer, Radiotherapy Sponsors : Fondazione Policlinico Uni
Comments
Sign in to join the conversation.
No comments yet. Be the first.